Impact of prior anthracycline or taxane use on eribulin effectiveness as first-line treatment for metastatic breast cancer: results from two phase 2, multicenter, single-arm studies

Metastatic Breast ◽

Line Treatment ◽

Phase 2 ◽

First Line ◽

Two Phase ◽

Metformin plus chemotherapy versus chemotherapy alone in the first-line treatment of HER2-negative metastatic breast cancer. The MYME randomized, phase 2 clinical trial

Breast Cancer Research and Treatment ◽

10.1007/s10549-018-05070-2 ◽

2018 ◽

Vol 174 (2) ◽

pp. 433-442 ◽

Cited By ~ 17

Author(s):

O. Nanni ◽

◽

D. Amadori ◽

A. De Censi ◽

A. Rocca ◽

...

Keyword(s):

Breast Cancer ◽

Clinical Trial ◽

Metastatic Breast ◽

Line Treatment ◽

Phase 2 ◽

First Line ◽

Phase 2 Clinical Trial ◽

Randomized Phase 2 ◽

Capecitabine-Based Chemoendocrine Combination as First-Line Treatment for Metastatic Hormone-Positive Metastatic Breast Cancer: Phase 2 Study

Clinical Breast Cancer ◽

10.1016/j.clbc.2019.12.012 ◽

2020 ◽

Vol 20 (3) ◽

pp. 228-237 ◽

Cited By ~ 1

Author(s):

Noha Rashad ◽

Thoraya Abdelhamid ◽

Samia A. Shouman ◽

Hanan Nassar ◽

Mervat A. Omran ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Line Treatment ◽

Phase 2 ◽

First Line ◽

Phase 2 Study ◽

Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: A multicentre, open-label, randomised phase 2 trial

European Journal of Cancer ◽

10.1016/j.ejca.2014.10.008 ◽

2014 ◽

Vol 50 (18) ◽

pp. 3077-3088 ◽

Cited By ~ 16

Author(s):

S.W. Lam ◽

S.M. de Groot ◽

A.H. Honkoop ◽

A. Jager ◽

A.J. ten Tije ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Line Treatment ◽

Phase 2 ◽

First Line ◽

Open Label ◽

Phase 2 Trial ◽

Locally Recurrent ◽

5060 POSTER Albumin-bound Paclitaxel (ab-pac) Versus Docetaxel for First-line Treatment of Metastatic Breast Cancer (MBC): Overall Survival (OS) Subset Analyses of a Randomized Phase 2 Trial

European Journal of Cancer ◽

10.1016/s0959-8049(11)71502-7 ◽

2011 ◽

Vol 47 ◽

pp. S348

Author(s):

W.J. Gradishar ◽

D.A. Krasnojon ◽

S.V. Cheporov ◽

A.N. Makhson ◽

G.M. Manikhas ◽

...

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

Metastatic Breast ◽

Line Treatment ◽

Phase 2 ◽

First Line ◽

Phase 2 Trial ◽

Randomized Phase 2 ◽

Clinical effects of prior anthracycline or taxane use on eribulin as first-line treatment for HER+/- locally recurrent or metastatic breast cancer (BC): Results from two phase II, multicenter, single-arm studies.

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.629 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. 629-629

Author(s):

Stefan Gluck ◽

Joyce O'Shaughnessy ◽

Kristi McIntyre ◽

Lee Steven Schwartzberg ◽

Sharon Wilks ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Metastatic Breast ◽

Clinical Effects ◽

Line Treatment ◽

First Line ◽

Two Phase ◽

Locally Recurrent ◽

Targeting HSP90 in breast cancer: Enchant-1 (NCT01677455) phase 2 proof of concept study of ganetespib in first-line treatment of women with metastatic breast cancer.

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.tps665 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. TPS665-TPS665 ◽

Cited By ~ 1

Author(s):

David A. Cameron ◽

Neil Spector ◽

Javier Cortes ◽

Max S. Mano ◽

Jean-Luc Re Canon ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Line Treatment ◽

Phase 2 ◽

Proof Of Concept ◽

First Line ◽

Concept Study ◽

Abstract P5-15-03:nab-paclitaxel + carboplatin or gemcitabine vs gemcitabine/carboplatin as first-line treatment for patients with triple-negative metastatic breast cancer: Results from the randomized phase 2 portion of the tnAcity trial

10.1158/1538-7445.sabcs16-p5-15-03 ◽

2017 ◽

Cited By ~ 6

Author(s):

D Yardley ◽

R Coleman ◽

P Conte ◽

J Cortes ◽

A Brufsky ◽

...

Keyword(s):

Breast Cancer ◽

Triple Negative ◽

Metastatic Breast ◽

Line Treatment ◽

Phase 2 ◽

First Line ◽

Randomized Phase 2 ◽

Efficacy and CNS progression analysis from the randomized phase 2 trial of neratinib + paclitaxel vs trastuzumab + paclitaxel as first-line treatment for HER2+ metastatic breast cancer (NEfERTT).

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.610 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. 610-610 ◽

Cited By ~ 3

Author(s):

Ahmad Awada ◽

Ramon Colomer ◽

Igor Bondarenko ◽

Kenichi Inoue ◽

Rajendra A. Badwe ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Line Treatment ◽

Phase 2 ◽

First Line ◽

Phase 2 Trial ◽

Randomized Phase 2 ◽

Abstract OT3-1-11: tnAcity: A phase 2/3 randomized study of weekly nab-paclitaxel in combination with either gemcitabine or carboplatin vs gemcitabine/carboplatin as first-line treatment for triple-negative metastatic breast cancer

10.1158/0008-5472.sabcs13-ot3-1-11 ◽

2013 ◽

Cited By ~ 1

Author(s):

DA Yardley ◽

A Brufsky ◽

P Conte ◽

J Cortes ◽

S Glück ◽

...

Keyword(s):

Breast Cancer ◽

Triple Negative ◽

Randomized Study ◽

Metastatic Breast ◽

Line Treatment ◽

Phase 2 ◽

First Line ◽

Faculty of 1000 evaluation for Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial.

F1000 - Post-publication peer review of the biomedical literature ◽

10.3410/f.717976445.793471388 ◽

2013 ◽

Author(s):

Ana Maria Gonzalez-Angulo

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Phase 3 ◽